Sheng Yao PhD, Chief Executive Officer and Executive Director

  • Co-founder of Shanghai Junshi Pharma and TopAlliance Biosciences
  • Research fellow in immunology at the Mayo Clinic College of Medicine and Johns Hopkins University
  • Trained under the guidance of immunotherapy pioneer, Dr. Lieping Chen
  • B.S. Biotechnology from Peking University and PhD from Albert Einstein College of Medicine

Hui Feng PhD, Chief Operating Officer and Executive Director

  • Co-founder of Shanghai Junshi Pharma and TopAlliance Biosciences
  • Post-Doctoral Researcher at Albert Einstein College of Medicine.
  • B.S Degree from Tsinghua University and PhD in Molecular Pharmacology from Albert Einstein College of Medicine

Patricia Keegan MD, Chief Medical Officer

  • Former Acting Associate Director of Medical Policy Oncology Center for Excellence (OCE), Office of the commissioner
  • Division Director of Oncology Products (16 years)
  • Deputy Director Division of Clinical Trial Design and Analysis (4 years)
  • Chief and Medical officer at Oncology Branch (8 years)
  • Clinical Assistance Professor and medical oncologist at University of North Carolina at Chapel Hill
  • B.S in Biology from University of Illinois Champaign-Urbana and M.D. from Loyola University Stritch School of Medicine
  • Completed her residency in internal medicine at the Loyola University Medical Center, Maywood, Illinois, and her fellowship in medical oncology at Roswell Park Memorial Institute, Buffalo, New York

Jian Yao PhD, Vice President of Research and Development

  • Responsible for the translational and development functions.
  • Oversees new target validation and antibody discovery through pre-clinical development.
  • Participated in the development of multiple programs that advanced to clinical and pre-clinical stages
  • B.S  from the University of Science and Technology of China and PhD degree from the University of Texas Southwestern Medical Center at Dallas

Ellen V. Maher MD, Vice President of Medical Sciences

  • Former Executive Director and Principal Clinical Consultant at DataRevive.
  • Former Team Leader at the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research (CDER) at FDA.
  • Former Team Leader in the Office of Cell, Tissue, and Gene Therapy in the Center for Biologics Evaluation and Research (CBER) at FDA.
  • During her tenure at the FDA, Dr. Maher served as the chief clinical reviewer for several blockbuster cancer drugs, such as bevacizumab, pazopanib, crizotinib, avelumab, atezolizumab, and durvalumab.
  • Former Medical Oncologist at Schering-Plough Institute, the National Cancer Institute and the Tulane Medical Center.
  • Received Doctorate of Medicine from the Temple University School of Medicine, completed medical residency at the Washington Hospital Center and Hematology/Medical Oncology fellowship at the University of Massachusetts Medical Center.

Independent Non-Executive Directors

Lieping Chen MD PhD

  • Member of Strategic Committee

Roy Herbst MD PhD

  • Member of Strategic Committee

Chen Xinjun

  • Chairman of Nomination Committee & Member of Audit Committee and Remuneration Committee

Qian Zhi

  • Member of Audit Committee, Remuneration Committee and Nomination Committee

He Jia

  • Chairman of Audit Committee and Remuneration Committee & Member of Strategic Committee